Sign In
Buy MORF
$56.99
+0 (+0%)
At Close: Nov 14, 2024
Morphic Therapeutic to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference
08:00am, Wednesday, 30'th Dec 2020
WALTHAM, Mass., Dec. 30, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing oral integrin therapies, today announced that Praveen Tipirneni, M.D., presiden
Morphic Holding's (MORF) Shares March Higher, Can It Continue?
09:02am, Tuesday, 15'th Dec 2020
As of late, it has definitely been a great time to be an investor in Morphic Holding (MORF).
Morphic Therapeutic to Present at the Jefferies Virtual London Healthcare Conference
09:05am, Tuesday, 17'th Nov 2020
WALTHAM, Mass., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment of
Morphic Announces Corporate Highlights and Third Quarter 2020 Financial Results
07:00am, Monday, 09'th Nov 2020
Initiated p hase 1 clinical trial for MORF-057 with results expected by mid-2021
Morphic Holding, Inc. (MORF) Reports Q2 Loss, Tops Revenue Estimates
12:35pm, Monday, 10'th Aug 2020
Morphic Holding, Inc. (MORF) delivered earnings and revenue surprises of 13.33% and 37.38%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Morphic Announces Corporate Highlights and Second Quarter 2020 Financial Results
11:00am, Monday, 10'th Aug 2020
Company’s first IND accepted by FDA for MORF-057 in IBD Phase 1 study expected to begin in third-quarter 2020 Positive data presented at DDW 2020 further support MORF-057 preclinical profile WALTH
Schrödinger, Inc. Reports Second Quarter 2020 Financial Results and Business Updates
12:00am, Monday, 10'th Aug 2020
Schrödinger today announced financial results for the second quarter ended June 30, 2020.
Morphic Holding's (NASDAQ:MORF) Stock Price Has Reduced13% In The Past Year
07:34pm, Friday, 07'th Aug 2020
It is a pleasure to report that the Morphic Holding, Inc. (NASDAQ:MORF) is up 58% in the last quarter. But that...
Morphic Holding, Inc. (MORF) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
04:31pm, Monday, 03'rd Aug 2020
Morphic Holding, Inc. (MORF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Receptor occupancy, potency and selectivity data further build MORF-057 preclinical profile as an oral small molecule treatment candidate for IBD IND filing on track for.
Morphic Holding (MORF) Investor Presentation - Slideshow
02:49pm, Wednesday, 24'th Jun 2020Morphic to Present at the BMO 2020 Prescriptions for Success Healthcare Virtual Conference
12:00pm, Thursday, 18'th Jun 2020
Morphic Therapeutic (MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment of serious chronic diseases, today announced that Praveen T
Hedge Funds Nibbling On Morphic Holding, Inc. (MORF)
01:36am, Tuesday, 16'th Jun 2020
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW).
Morphic to Present at the Jefferies Virtual Healthcare Conference
12:00pm, Wednesday, 27'th May 2020
Morphic Therapeutic (MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment of serious chronic diseases, today announced that the Morph
Morphic Announces Corporate Highlights and First Quarter 2020 Financial Results
08:05pm, Wednesday, 06'th May 2020
Data presented at ECCO Congress support MORF-057 in IBD; IND on track for mid-year Recent executive appointments of Peter Linde, M.D., as CMO and Marc Schegerin, M.D., as.
